Ascentage Pharma Group International Unsponsored ADR (AAPG)
NASDAQ:AAPG
Want to see AAPG full AI Analyst Report?
Top Page
Ascentage Pharma Group International Unsponsored ADR
(NASDAQ:AAPG)
Select Model
Select Model
Rating:40Underperform
Price Target:
$18.00
▼(-34.31% Downside)
Action:Downgraded
Date:05/04/26
The score is primarily constrained by weak financial performance driven by persistent and worsening losses and significant cash burn, despite strong revenue growth and high gross margins. Technicals also reflect a weak trend with negative momentum. Valuation is further pressured by a negative P/E and no dividend yield data.
Positive Factors
Commercial-stage products in China
Having approved, revenue-generating products in China establishes a commercial foothold and recurring revenue potential that de-risks the pipeline. This durable market presence supports funding for global registrational trials and provides operating scale while the company expands indications and geographies.
Negative Factors
Large and accelerating cash burn
Consistent, steep negative operating and free cash flows create persistent funding needs. This structural cash burn increases the probability of dilution or restrictive financing terms, limits flexibility to scale commercialization, and forces management to prioritize capital allocation toward survival and trials.
Read all positive and negative factors
Positive Factors
Negative Factors
Commercial-stage products in China
Having approved, revenue-generating products in China establishes a commercial foothold and recurring revenue potential that de-risks the pipeline. This durable market presence supports funding for global registrational trials and provides operating scale while the company expands indications and geographies.
Read all positive factors
Ascentage Pharma Group International Unsponsored ADR (AAPG) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$1.97B
Dividend YieldN/A
Average Volume (3M)8.43K
Price to Earnings (P/E)―
Beta (1Y)0.66
Revenue Growth-41.19%
EPS Growth-159.09%
CountryUS
Employees567
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-13.84
Shares Outstanding93,333,690
10 Day Avg. Volume7,086
30 Day Avg. Volume8,425
Financial Highlights & Ratios
PEG Ratio-0.09
Price to Book (P/B)12.33
Price to Sales (P/S)29.25
P/FCF Ratio-13.59
Enterprise Value/Market Cap6.49
Enterprise Value/Revenue22.51
Enterprise Value/Gross Profit26.76
Enterprise Value/Ebitda-11.48
Forecast
1Y Price Target
$41.56Price Target Upside51.67% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-1.1
Revenue Forecast (FY)$134.34M
Ascentage Pharma Group International Unsponsored ADR Business Overview & Revenue Model
Company Description
Ascentage Pharma Group International, a clinical-stage biotechnology company, develops therapies for cancers, chronic hepatitis B virus (HBV), and age-related diseases in Mainland China. The company's primary product candidate is HQP1351, a BCR-AB...
How the Company Makes Money
null...
Ascentage Pharma Group International Unsponsored ADR Financial Statement Overview
Summary
Income Statement
24
Negative
Balance Sheet
38
Negative
Cash Flow
18
Very Negative
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 558.48M | 980.65M | 221.98M | 209.71M | 27.91M |
| Gross Profit | 426.75M | 951.57M | 191.44M | 187.71M | 24.58M |
| EBITDA | -1.10B | -237.63M | -743.61M | -786.97M | -798.34M |
| Net Income | -1.21B | -405.43M | -925.64M | -882.92M | -782.42M |
Balance Sheet | |||||
| Total Assets | 3.97B | 2.62B | 2.50B | 2.83B | 2.94B |
| Cash, Cash Equivalents and Short-Term Investments | 2.47B | 1.24B | 1.07B | 1.48B | 1.71B |
| Total Debt | 1.98B | 1.67B | 1.80B | 1.79B | 1.08B |
| Total Liabilities | 2.63B | 2.34B | 2.43B | 2.42B | 1.71B |
| Stockholders Equity | 1.33B | 264.19M | 60.42M | 408.66M | 1.23B |
Cash Flow | |||||
| Free Cash Flow | -1.20B | -135.65M | -782.92M | -890.88M | -1.04B |
| Operating Cash Flow | -1.17B | -111.36M | -726.08M | -653.91M | -604.68M |
| Investing Cash Flow | -1.00B | -362.04M | 21.92M | -384.61M | -466.52M |
| Financing Cash Flow | 2.54B | 314.77M | 368.75M | 619.27M | 1.78B |
Ascentage Pharma Group International Unsponsored ADR Technical Analysis
Negative
27.40
Price Trends
37.24
Negative
38.97
Negative
Market Momentum
-1.44
Positive
34.89
Neutral
11.49
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AAPG, the sentiment is Negative. The current price of 27.4 is below the 20-day moving average (MA) of 34.27, below the 50-day MA of 37.24, and equal to the 200-day MA of ―, indicating a neutral trend. The MACD of -1.44 indicates Positive momentum. The RSI at 34.89 is Neutral, neither overbought nor oversold. The STOCH value of 11.49 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for AAPG.
Ascentage Pharma Group International Unsponsored ADR Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
62 Neutral | $7.01B | -8.96 | -65.80% | ― | ― | -1.22% | |
55 Neutral | $3.88B | -7.39 | -43.96% | ― | 4905.26% | -34.49% | |
54 Neutral | $1.34B | -4.76 | -85.61% | ― | ― | -68.11% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $6.49B | -29.33 | -25.02% | ― | -12.58% | -15.21% | |
49 Neutral | $6.56B | 453.36 | -17.76% | ― | -64.36% | -302.09% | |
40 Underperform | $1.97B | -13.51 | -123.61% | ― | -41.19% | -159.09% |
* Healthcare Sector Average
AAPG
Ascentage Pharma Group International Unsponsored ADR
21.01
-4.81
-18.63%
PTGX
Protagonist Therapeutics
99.19
52.76
113.63%
CRNX
Crinetics Pharmaceuticals
36.80
7.30
24.75%
IMVT
Immunovant
34.15
19.86
138.98%
KYMR
Kymera Therapeutics
78.89
50.75
180.35%
MLTX
MoonLake Immunotherapeutics
18.19
-20.39
-52.85%
Ascentage Pharma Group International Unsponsored ADR Corporate Events
Ascentage Pharma to Present 17 Hematology Clinical Updates at June 2026 EHA Congress
May 13, 2026
On May 12, 2026, Ascentage Pharma Group International, a global biopharmaceutical company specializing in innovative oncology therapies, announced that 17 clinical advances from its core assets will be showcased at the 31st European Hematology Ass...
Ascentage Pharma to Highlight Oncology Portfolio at May–June 2026 Investor Conferences
May 12, 2026
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company specializing in innovative oncology therapies, including apoptotic pathway inhibitors, next-generation kinase inhibitors and protein degraders. Its lead p...
Ascentage Pharma Sets March 25 Board Meeting on 2025 Results and Potential Final Dividend
Mar 16, 2026
On March 13, 2026, Ascentage Pharma Group International announced that its board of directors will convene a meeting on March 25, 2026 to review and, if appropriate, approve the group’s audited annual results for the year ended December 31, ...
Ascentage Pharma Sets March 25, 2026 Date to Unveil 2025 Unaudited Results and Business Update
Mar 11, 2026
On March 11, 2026, Ascentage Pharma announced that it will report its unaudited financial results for the full year 2025 and deliver business updates on March 25, 2026, U.S. time, or March 26, 2026, Hong Kong time. The disclosure will be accompani...
Ascentage Pharma Ramps Up Investor Outreach With Three U.S. Conferences
Feb 23, 2026
On February 23, 2026, Ascentage Pharma announced that its management will present at three investor conferences in late February and March, including the Oppenheimer Healthcare Life Sciences Conference, the TD Cowen Health Care Conference, and the...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.